Emyria LtdASX: EMD

2026 Annual General Meeting Presentation

· Issued by Emyria Ltd via ASX

Filed with ASX · · 9 pages · English

Summary by 6ix AI

The company reported a substantial increase in revenue compared to the previous year, driven by the expansion of its clinic network. Emyria is focusing on leveraging momentum in psychedelic drug treatments and has appointed a strategic advisor to enhance its US opportunities. The presentation outlines recent achievements and future drivers for growth, emphasizing the company's commitment to shareholders.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX : EMD Delivering the new paradigm in mental health care 2026 Annual General Meeting Presentation November 2026 1 Advanced therapies. Compassionate care. Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial...

Emyria Ltd on 6ix

In the deck

Story so far

Earlier from Emyria

Later from Emyria

All Emyria news releases